ImmunityBio Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • ImmunityBio's estimated annual revenue is currently $1.5M per year.(i)
  • ImmunityBio's estimated revenue per employee is $2,275
  • ImmunityBio's current valuation is $2.7B. (January 2022)

Employee Data

  • ImmunityBio has 655 Employees.(i)
  • ImmunityBio grew their employee count by -6% last year.

ImmunityBio's People

NameTitleEmail/Phone
1
Chief Medical OfficerReveal Email/Phone
2
Chief Accounting Officer (CAO)Reveal Email/Phone
3
VP BiometricsReveal Email/Phone
4
VP Product Development, Cell Therapy ProgramReveal Email/Phone
5
General Counsel and Corporate SecretaryReveal Email/Phone
6
VP, Technical Accounting and Financial ReportingReveal Email/Phone
7
VP, Associate General Counsel, TransactionsReveal Email/Phone
8
VP ManufacturingReveal Email/Phone
9
Head Computational BiologyReveal Email/Phone
10
SVP, Product Development & Vaccine ProgramsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is ImmunityBio?

Leading late-stage immunotherapy company harnessing immunogenic cell death by orchestrating both the innate (NK) and adaptive (T Cell) immune system through first-in-class immunological platforms. ImmunityBio (formerly NantCell) develops novel combinations of chemo-immune sensitizers, cell therapies, cytokines, vaccines, neoepitopes, and monoclonal antibody immunotherapies to orchestrate the NK and T Cell response for cancer and infectious diseases.

keywords:N/A

N/A

Total Funding

655

Number of Employees

$1.5M

Revenue (est)

-6%

Employee Growth %

$2.7B

Valuation

N/A

Accelerator

ImmunityBio News

2022-04-20 - ImmunityBio To Present Data From Multiple Clinical Trials at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Data from ImmunityBio's QUILT 3.032 BCG-unresponsive non-muscle invasive bladder cancer trial will be presented by principal investigator in...

2022-04-17 - ImmunityBio Announces First Participants Have Been Enrolled in Lung-MAP Trial Studying Anktiva to Activate NK and T Cells in Non-Small Cell Lung Cancer

ImmunityBio Announces First Participants Have Been Enrolled in Lung-MAP Trial Studying Anktiva to Activate NK and T Cells in Non-Small Cell Lung...

2022-03-22 - ImmunityBio Provides Updated Status of Biologics License ...

ImmunityBio is a clinical-stage biotechnology company developing next-generation therapies and vaccines that bolster the natural immune...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$265M7013%N/A
#2
$236.4M72529%$670M
#3
$304.3M80510%N/A
#4
$15M82210%N/A
#5
$298.5M93518%N/A